title: [Chemotherapy in malignant gliomas].
abstract: Considering the survival time of patients with malignant gliomas indication for chemotherapy in spite of side effects is recommended. One third of them are living 2 years, some even longer. Before starting such a treatment a critical evaluation is mandatory, a prolongation of dying must be avoided. In addition personal human care to the patient and his family has a great importance.
authors.affiliation: Neurologische Universitätsklinik Kiel.
authors.forename: K
authors.initials: K
authors.lastname: Heuser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000627:therapeutic use; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D015376:Nimustine / Q000627:therapeutic use; D015996:Survival Rate; D013713:Teniposide / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D015376:Nimustine; D013713:Teniposide; D002330:Carmustine
vernacular_title: Chemotherapie bei malignen Gliomen.